A5056367620- Venous Thromboembolism Diagnosis and Management
- COVID-19 Clinical Research Studies
- Atrial Fibrillation Management and Outcomes
- COVID-19 and healthcare impacts
- Heparin-Induced Thrombocytopenia and Thrombosis
- Systemic Lupus Erythematosus Research
- Case Reports on Hematomas
- Cardiac electrophysiology and arrhythmias
- Acute Myocardial Infarction Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Complement system in diseases
- Sepsis Diagnosis and Treatment
- Intramuscular injections and effects
- Ophthalmology and Eye Disorders
- Hepatitis C virus research
- Blood disorders and treatments
- Vascular Malformations and Hemangiomas
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Eosinophilic Disorders and Syndromes
- Platelet Disorders and Treatments
- Pharmaceutical Economics and Policy
- Infectious Aortic and Vascular Conditions
- Cardiovascular Syncope and Autonomic Disorders
- Systemic Sclerosis and Related Diseases
- Iron Metabolism and Disorders
Hôpital Lariboisière
2017-2025
Assistance Publique – Hôpitaux de Paris
2017-2025
Inserm
2025
Université Paris Cité
2017-2024
Hôpital Saint-Louis
2019-2024
Institut de recherche Saint-Louis
2020-2024
Hôpital Paris Saint-Joseph
2016-2024
Hôpital Marie Lannelongue
2024
Sorbonne Paris Cité
2022
Recherche clinique appliquée à l'hématologie
2020-2021
Venous thromboembolism is a major complication of coronavirus disease 2019 (COVID-19). We hypothesized that weight-adjusted intermediate dose anticoagulation may decrease the risk venous COVID-19 patients.In this multicenter, randomised, open-label, phase 4, superiority trial with blinded adjudication outcomes, we randomly assigned adult patients hospitalised in 20 French centers and presenting acute respiratory SARS-CoV-2. Eligible were (1:1 ratio) to receive an prophylactic or fixed-dose...
Patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)- have been reported to develop endothelium injury, an excessive inflammatory response and subsequent marked hypercoagulability, leading a high prevalence of venous thromboembolic events (VTE), up c. 50% in cases.1, 2 von Willebrand factor (VWF) is known as major cause thrombo-inflammation via mechanisms including endothelial activation, enhanced VWF secretion, assembly hyper adhesive multimers, defective cleavage by...
Background Although a growing number of very elderly patients with atrial fibrillation (AF), multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few studies specifically investigated both apixaban/rivaroxaban pharmacokinetics pharmacodynamics in such patients. Aims To investigate: (1) DOAC concentration–time profiles; (2) thrombin generation (TG); (3) clinical outcomes 6 months after inclusion AF in-patients receiving rivaroxaban or apixaban. Methods...
The presence of dextran sulfate (DS) in reagents and the type blood collection tube (citrate/citrated-theophylline-adenosine-dipyridamole [CTAD]) can lead to discrepancies between unfractionated heparin (UFH) anti-Xa levels. To evaluate extent effect (1) different containing or not DS (2) tubes, on UFH levels, various clinical situations (NCT04700670). We prospectively included patients from eight centers: group (G)1, cardiopulmonary bypass (CPB) after neutralization (n = 39); G2,...
The incidence of pulmonary embolism (PE) is high during severe Coronavirus Disease 2019 (COVID-19). We aimed to identify predictive and prognostic factors PE in non-ICU hospitalized COVID-19 patients. In the retrospective multicenter observational CLOTVID cohort, we enrolled patients with confirmed RT-PCR who were a medicine ward also underwent CT angiography for suspicion. Baseline data, laboratory biomarkers, treatments, outcomes collected. Predictive prognostics identified by using...
Abstract Background A high prevalence of pulmonary embolism (PE) has been described during COVID‐19. Our aim was to identify predictive factors PE in non‐ICU hospitalized COVID‐19 patients. Methods Data and outcomes were collected upon admission a French multicenter retrospective study, including patients for COVID‐19, with CT angiography (CTPA) performed the emergency department suspected PE. Predictive significantly associated identified through multivariate regression model. Results total...
Background and Purpose In patients with acute ischemic stroke (AIS) using a direct oral factor-Xa anticoagulant (DOAC) during the last 48 hours, fixed plasma heparin-calibrated anti-Xa activity (0.5 IU/mL) was proposed as threshold below which could be eligible for thrombolysis and/or thrombectomy. Besides, specific DOAC-calibrated thresholds up to 50 ng/mL have been proposed. However, DOAC assays are not widely available contrarily low-molecularweight heparin (LMWH) activity. We developed...
Direct oral anticoagulants (DOAC) are widely used due to favourable benefit/risk ratio. However, consequences of massive ingestion have been poorly investigated.We aimed report outcome and pharmacokinetic parameters in patients who massively ingested DOACs.We conducted a 5-year cohort study including consecutive DOAC admitted two critical care departments. Patients were managed accordance with standards care. We collected the main history, clinical, laboratory, management data. The...
Severe acute respiratory syndrome coronavirus 2 disease is strongly associated with a high incidence of thrombotic events. Anticoagulation could be cornerstone in successfully managing severe forms 2019 (COVID-19). However, optimal anticoagulant dosing elderly patients challenging because risk both thrombosis and bleeding.We present here the case an 89-year-old patient receiving warfarin for atrial fibrillation valvular heart disease, admitted to intensive care unit failure due COVID-19. The...